TScan Therapeutics is laying off about 30% of staff and stopping a Phase I solid‑tumor T‑cell receptor trial to prioritize blood‑cancer programs and preserve runway. The company told investors it will redeploy resources toward candidates with clearer paths to approval. The restructuring follows disappointing strategic outcomes and broader industry pressure on early‑stage immuno‑oncology firms to demonstrate near‑term value or secure partnerships. TScan’s move includes program terminations and an explicit refocus on nearer‑term clinical readouts. Analysts said the downsizing echoes a wider biotech trend where capital scarcity and trial risk force companies to narrow pipelines or seek buyers for noncore assets. Remaining employees will concentrate on advancing blood‑cancer assets and preparing for partnering discussions.